Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Dr Wildgust Discusses Racial Disparities in Treatment Patterns, Outcomes in MM

Mark Wildgust, PhD, reviews real-world evidence examining potential healthcare disparities- highlighting patient characteristics, treatment patterns and outcomes for Black and White patients with multiple myeloma who initiated treatment with daratumumab, presented at the 2021 Annual ASH Meeting. 
 

Disclaimer: The views and opinions expressed are those of the author(s) and do not necessarily reflect the official policy or position of Oncology Learning Network or HMP Global, their employees, and affiliates. Any content provided by our bloggers or authors are of their opinion and are not intended to malign any religion, ethnic group, club, association, organization, company, individual, anyone, or anything.

 

Advertisement

Advertisement

Advertisement

Advertisement